BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30987970)

  • 21. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor.
    Reinart N; Nguyen PH; Boucas J; Rosen N; Kvasnicka HM; Heukamp L; Rudolph C; Ristovska V; Velmans T; Mueller C; Reiners KS; von Strandmann EP; Krause G; Montesinos-Rongen M; Schlegelberger B; Herling M; Hallek M; Fingerle-Rowson G
    Blood; 2013 Jan; 121(5):812-21. PubMed ID: 23118218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.
    DiLillo DJ; Weinberg JB; Yoshizaki A; Horikawa M; Bryant JM; Iwata Y; Matsushita T; Matta KM; Chen Y; Venturi GM; Russo G; Gockerman JP; Moore JO; Diehl LF; Volkheimer AD; Friedman DR; Lanasa MC; Hall RP; Tedder TF
    Leukemia; 2013 Jan; 27(1):170-82. PubMed ID: 22713648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.
    Herling M; Patel KA; Weit N; Lilienthal N; Hallek M; Keating MJ; Jones D
    Blood; 2009 Nov; 114(21):4675-86. PubMed ID: 19770358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polysome-CAGE of TCL1-driven chronic lymphocytic leukemia revealed multiple N-terminally altered epigenetic regulators and a translation stress signature.
    Ogran A; Havkin-Solomon T; Becker-Herman S; David K; Shachar I; Dikstein R
    Elife; 2022 Aug; 11():. PubMed ID: 35939046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia.
    Bresin A; D'Abundo L; Narducci MG; Fiorenza MT; Croce CM; Negrini M; Russo G
    Cell Death Dis; 2016 Jan; 7(1):e2071. PubMed ID: 26821067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.
    Balatti V; Rizzotto L; Miller C; Palamarchuk A; Fadda P; Pandolfo R; Rassenti LZ; Hertlein E; Ruppert AS; Lozanski A; Lozanski G; Kipps TJ; Byrd JC; Croce CM; Pekarsky Y
    Proc Natl Acad Sci U S A; 2015 Feb; 112(7):2169-74. PubMed ID: 25646413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
    Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
    Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Sleeping Beauty screen reveals NF-kB activation in CLL mouse model.
    Zanesi N; Balatti V; Riordan J; Burch A; Rizzotto L; Palamarchuk A; Cascione L; Lagana A; Dupuy AJ; Croce CM; Pekarsky Y
    Blood; 2013 May; 121(21):4355-8. PubMed ID: 23591791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL).
    Palamarchuk A; Yan PS; Zanesi N; Wang L; Rodrigues B; Murphy M; Balatti V; Bottoni A; Nazaryan N; Alder H; Rassenti L; Kipps TJ; Freitas M; Croce CM; Pekarsky Y
    Proc Natl Acad Sci U S A; 2012 Feb; 109(7):2555-60. PubMed ID: 22308499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.
    Motiwala T; Zanesi N; Datta J; Roy S; Kutay H; Checovich AM; Kaou M; Zhong Y; Johnson AJ; Lucas DM; Heerema NA; Hagan J; Mo X; Jarjoura D; Byrd JC; Croce CM; Jacob ST
    Blood; 2011 Dec; 118(23):6132-40. PubMed ID: 22001392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TBET-expressing Th1 CD4
    Roessner PM; Hanna BS; Öztürk S; Schulz R; Llaó Cid L; Yazdanparast H; Scheffold A; Colomer D; Stilgenbauer S; Lichter P; Seiffert M
    Br J Haematol; 2020 Apr; 189(1):133-145. PubMed ID: 31724172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.
    Yan XJ; Albesiano E; Zanesi N; Yancopoulos S; Sawyer A; Romano E; Petlickovski A; Efremov DG; Croce CM; Chiorazzi N
    Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11713-8. PubMed ID: 16864779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.
    Holler C; Piñón JD; Denk U; Heyder C; Hofbauer S; Greil R; Egle A
    Blood; 2009 Mar; 113(12):2791-4. PubMed ID: 19168795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia.
    Fedorchenko O; Stiefelhagen M; Peer-Zada AA; Barthel R; Mayer P; Eckei L; Breuer A; Crispatzu G; Rosen N; Landwehr T; Lilienthal N; Möllmann M; Montesinos-Rongen M; Heukamp L; Dürig J; Hallek M; Fingerle-Rowson G; Herling M
    Blood; 2013 May; 121(20):4126-36. PubMed ID: 23547049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the splenic microenvironment in chronic lymphocytic leukemia development in Eµ-TCL1 transgenic mice.
    Collard JP; McKenna MK; Noothi SK; Alhakeem SS; Rivas JR; Rangnekar VM; Muthusamy N; Bondada S
    Leuk Lymphoma; 2022 Aug; 63(8):1810-1822. PubMed ID: 35258388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.
    Pekarsky Y; Santanam U; Cimmino A; Palamarchuk A; Efanov A; Maximov V; Volinia S; Alder H; Liu CG; Rassenti L; Calin GA; Hagan JP; Kipps T; Croce CM
    Cancer Res; 2006 Dec; 66(24):11590-3. PubMed ID: 17178851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic alterations in a murine model for chronic lymphocytic leukemia.
    Chen SS; Sherman MH; Hertlein E; Johnson AJ; Teitell MA; Byrd JC; Plass C
    Cell Cycle; 2009 Nov; 8(22):3663-7. PubMed ID: 19901553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.
    Lewis R; Maurer HC; Singh N; Gonzalez-Menendez I; Wirth M; Schick M; Zhang L; Isaakidis K; Scherger AK; Schulze V; Lu J; Zenz T; Steiger K; Rad R; Quintanilla-Martinez L; Espeli M; Balabanian K; Keller U; Habringer S
    Leukemia; 2021 Oct; 35(10):2895-2905. PubMed ID: 34363012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
    Gutjahr JC; Szenes E; Tschech L; Asslaber D; Schlederer M; Roos S; Yu X; Girbl T; Sternberg C; Egle A; Aberger F; Alon R; Kenner L; Greil R; Orian-Rousseau V; Hartmann TN
    Blood; 2018 Mar; 131(12):1337-1349. PubMed ID: 29352038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.
    Grioni M; Brevi A; Cattaneo E; Rovida A; Bordini J; Bertilaccio MTS; Ponzoni M; Casorati G; Dellabona P; Ghia P; Bellone M; Calcinotto A
    Blood Adv; 2021 Jul; 5(14):2817-2828. PubMed ID: 34269799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.